Novartis Revises Zelnorm Labeling With Diarrhea, Ischemic Colitis Risk Info

Novartis has revised labeling for the irritable bowel syndrome therapy Zelnorm to include the risk of developing severe diarrhea and ischemic colitis, FDA says in a 1"Talk Paper" issued April 28

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet